Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 676 - 700 of 15222 in total
Pramiracetam has been previously approved in some eastern European countries under the brand names Pramistar, Neupramir, and Remen. It was also previously approved in the United States with orphan drug designation . Pramiracetam has been studied for the use in Alzheimer's disease and as an adjunct treatment to restore cognitive...
Approved
Matched Description: … previously approved in some eastern European countries under the brand names Pramistar, Neupramir, and ... Pramiracetam has been studied for the use in Alzheimer's disease and as an adjunct treatment to restore …
Matched Categories: … Psychostimulants, Agents Used for ADHD and Nootropics …
Dibenzepin is approved for use in Europe.
Approved
Approved
Experimental
Remoxipride is an atypical antipsychotic agent that is specific for dopamine D2 receptors. It gained approval in the UK in 1989 but was withdrawn in 1993 after it was found to be associated with an increased incidence of aplastic anemia.[A215422,A215512]
Approved
Withdrawn
Matched Categories: … Benzamides and benzamide derivatives …
A long-acting injectable antipsychotic agent used for chronic schizophrenia.
Approved
Investigational
Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times higher than that of the first generation...
Approved
Investigational
Matched Description: … [L6676] Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. ... [A179398] It is most commonly marketed under the name Inlyta® and is available in oral formulations. …
Matched Categories: … Benzamides and benzamide derivatives ... Antineoplastic and Immunomodulating Agents …
A synthetic broad-spectrum fluoroquinolone antibacterial agent active against most gram-negative and gram-positive bacteria.
Approved
Matched Iupac: … 1-ethyl-6-fluoro-7-(4-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
Matched Description: … A synthetic broad-spectrum fluoroquinolone antibacterial agent active against most gram-negative and
Matched Categories: … Metabolic Side Effects of Drugs and Substances …
Mesuximide (or methsuximide) is an anticonvulsant medication. It is sold by Pfizer under the name Petinutin.
Approved
Tenoxicam, an antiinflammatory agent with analgesic and antipyretic properties, is used to treat osteoarthritis and control acute pain.
Approved
Matched Description: … and control acute pain. ... Tenoxicam, an antiinflammatory agent with analgesic and antipyretic properties, is used to treat osteoarthritis …
Matched Categories: … Antiinflammatory and Antirheumatic Products ... Antiinflammatory and Antirheumatic Products, Non-Steroids …
Gliquidone is a sulfonylurea drug used to treat diabetes mellitus type 2. It is an ATP-dependent K+ (KATP) channel blocker. This block causes a depolarization which leads to activation of voltage-dependent Ca channels and Ca2+ influx, and eventually increases insulin release.
Approved
Investigational
Matched Description: … + influx, and eventually increases insulin release. ... This block causes a depolarization which leads to activation of voltage-dependent Ca channels and Ca2 …
Matched Categories: … Alimentary Tract and Metabolism …
Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment of patients with unresectable or...
Approved
Investigational
Matched Description: … Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated ... It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment of ... protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Reslizumab is a humanized interleukin-5 (IL-5) antagonist monoclonal antibody (IgG4 kappa) that is produced by recombinant DNA technology in murine myeloma non-secreting 0 (NS0) cells. IL-5 is a pro-inflammatory cytokine that is responsible for the growth and differentiation, recruitment, activation, and survival of eosinophils [FDA Label]. Elevated levels of eosinophils...
Approved
Investigational
Matched Description: … and promote programmed cell death [A31578]. ... , activation, and survival of eosinophils [FDA Label]. ... for recurrent exacerbation and asthma-related hospitalizations [A31579]. …
Matched Categories: … Amino Acids, Peptides, and Proteins …
A quinazoline-sulfonamide that is considered a thiazide-like diuretic which is long-acting so useful in chronic renal failure. It also tends to lower blood pressure and increase potassium loss.
Approved
Matched Description: … It also tends to lower blood pressure and increase potassium loss. …
Matched Categories: … Genito Urinary System and Sex Hormones ... metolazone and potassium-sparing agents ... Gynecological Antiinfectives and Antiseptics ... Low-Ceiling Diuretics and Potassium-Sparing Agents …
A tetracycline analog having a 7-chloro and a 6-methyl. Because it is excreted more slowly than tetracycline, it maintains effective blood levels for longer periods of time.
Approved
Matched Description: … A tetracycline analog having a 7-chloro and a 6-methyl. …
Amikacin is a semi-synthetic aminoglycoside antibiotic that is derived from kanamycin A.[FDA label] Amikacin is synthesized by acylation with the l-(-)-γ-amino-α-hydroxybutyryl side chain at the C-1 amino group of the deoxystreptamine moiety of kanamycin A. Amikacin's unique property is that it exerts activity against more resistant gram-negative bacilli such as...
Approved
Investigational
Vet approved
Matched Description: … of breath and the coughing up of blood. ... some Mycobacterium (M. avium-intracellulare, M. chelonae, and M. fortuitum)[L4680]. ... that it exerts activity against more resistant gram-negative bacilli such as Acinetobacter baumanii and
Matched Categories: … cefepime and amikacin …
Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by pioglitazone and rosiglitazone.
Approved
Investigational
Withdrawn
Matched Description: … It was superseded by [pioglitazone] and [rosiglitazone]. …
Matched Categories: … Alimentary Tract and Metabolism …
An ethanolamine derivative that is an adrenergic alpha agonist. It is used as a vasoconstrictor agent in the treatment of hypotension.
Approved
Matched Categories: … Adrenergic and Dopaminergic Agents …
A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties.
Approved
Matched Description: … It also possesses some anticholinergic and local anesthetic properties. ... anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and
Telithromycin, a semi-synthetic erythromycin derivative, belongs to a new chemical class of antibiotics called ketolides. Ketolides have been recently added to the macrolide-lincosamide-streptogramin class of antibiotics. Similar to the macrolide antibiotics, telithromycin prevents bacterial growth by interfering with bacterial protein synthesis. Telithromycin binds to the 50S subunit of the 70S...
Approved
Matched Description: … Binding occurs simultaneously at to two domains of 23S RNA of the 50S ribosomal subunit, domain II and ... Telithromycin binds to the 50S subunit of the 70S bacterial ribosome and blocks further peptide elongation …
Matched Categories: … Erythromycin and similars ... Macrolides, Lincosamides and Streptogramins …
Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States.
Approved
Investigational
Withdrawn
Matched Iupac: … 1-cyclopropyl-6-fluoro-5-methyl-7-(3-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
Matched Description: … QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and
Lorazepam is a short-acting and rapidly cleared benzodiazepine used commonly as a sedative and anxiolytic. It was developed by DJ Richards, presented and marketed initially by Wyeth Pharmaceuticals in the USA in 1977. The first historic FDA label approval is reported in 1985 by the company Mutual Pharm.
Approved
Matched Description: … Lorazepam is a short-acting and rapidly cleared benzodiazepine used commonly as a sedative and anxiolytic ... [A957] It was developed by DJ Richards, presented and marketed initially by Wyeth Pharmaceuticals in …
Matched Categories: … Hypnotics and Sedatives ... Benzodiazepine hypnotics and sedatives ... Benzodiazepines and benzodiazepine derivatives …
A tetracycline analog isolated from the actinomycete streptomyces rimosus and used in a wide variety of clinical conditions.
Approved
Investigational
Vet approved
Matched Description: … A tetracycline analog isolated from the actinomycete streptomyces rimosus and used in a wide variety …
Matched Categories: … Alimentary Tract and Metabolism ... Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics ... Antiinfectives and Antiseptics for Local Oral Treatment …
The administration of quinidine derivatives helps to observe various skin and mucosal reactions. A papulopurpuric eruption in a patient (without thrombopenia) can be developed who is taking quinidine phenylethyl barbiturate intermittently and at reintroduction.(PMID: 9739909)
Approved
Matched Description: … The administration of quinidine derivatives helps to observe various skin and mucosal reactions. ... without thrombopenia) can be developed who is taking quinidine phenylethyl barbiturate intermittently and
Regadenoson is an A2A adenosine receptor agonist that causes coronary vasodilation and used for myocardial perfusion imagining. Manufactured by Astellas and FDA approved April 10, 2008.
Approved
Investigational
Matched Description: … Manufactured by Astellas and FDA approved April 10, 2008. ... Regadenoson is an A2A adenosine receptor agonist that causes coronary vasodilation and used for myocardial …
Dacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible binding at the ATP domain of the epidermal growth factor receptor family kinase domains. Dacomitinib was developed by Pfizer Inc and approved by the FDA on...
Approved
Investigational
Matched Description: … [A40009] Dacomitinib was developed by Pfizer Inc and approved by the FDA on September 27, 2018. …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Displaying drugs 676 - 700 of 15222 in total